News
The success of Vertex's opioid alternative Journavx could aid a group of biotechs that aim to take a similar path with NaV1.8 ...
Indeed, SiteOne and at least 10 other developers want to follow in Vertex’s footsteps with their own medicines that stopper either the “NaV1.8” sodium ion channel, as Journavx does, or a ...
In many lower-sodium salts like K-salt, the sodium is partially substituted with potassium. K-salt is set to hit supermarkets in early October 2022, and will retail at S$2.50 for a 400g pack.
Others working on sodium ion channel drugs for acute pain applications include Latigo Biotherapeutics, which raised $135 million in a Series A last year and has NaV1.8 inhibitors LTG-001 and LTG ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results